Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

35.72
+0.22000.62%
Post-market: 35.50-0.2200-0.62%19:30 EDT
Volume:4.37M
Turnover:155.72M
Market Cap:25.80B
PE:-76
High:36.00
Open:35.61
Low:35.19
Close:35.50
52wk High:42.50
52wk Low:15.25
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.76
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.10
PE(LYR):-66.15

Loading ...

Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000

Reuters
·
4 hours ago

Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer

Reuters
·
Oct 01

Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer

Reuters
·
Sep 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

TIPRANKS
·
Sep 27

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

TIPRANKS
·
Sep 24

Sector Update: Healthcare

MT Newswires Live
·
Sep 23

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Roivant Sciences price target raised to $41 from $37.50 at BofA

TIPRANKS
·
Sep 23

Immunovant Falls After Lupus Drug Setback

Reuters
·
Sep 23

Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE

Reuters
·
Sep 23

Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Sep 23

Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS
·
Sep 23

Roivant Sciences - All Other Clinical Development Timelines Remain on Track

THOMSON REUTERS
·
Sep 23

Roivant Sciences Holds Annual Shareholder Meeting

Reuters
·
Sep 18

Roivant Sciences Director Meghan FitzGerald Reports $203,159 Common Share Sale

Reuters
·
Sep 18

Stifel Nicolaus Initiates Roivant Sciences With Buy Rating, $51 Price Target

MT Newswires Live
·
Sep 17

Roivant Sciences Ltd : Stifel Initiates Coverage with Buy Rating; Target Price $51

THOMSON REUTERS
·
Sep 17

Roivant Sciences Price Target Announced at $51.00/Share by Stifel

Dow Jones
·
Sep 17

Roivant Sciences initiated with a Buy at Stifel

TIPRANKS
·
Sep 17

Roivant Sciences Ltd : Leerink Partners Raises Target Price to $52 from $42

THOMSON REUTERS
·
Sep 15